ITeos Therapeutics Doses First Patient in Phase 3 Trial of Belrestotug With Dostarlimab; Triggers $35 Million GSK Payment
ITeos Therapeutics Doses First Patient in Phase 3 Trial of Belrestotug With Dostarlimab; Triggers $35 Million GSK Payment
iteos therapeutics向配合dostarlimab使用的belrestotug進行三期臨床試驗，已給第一名患者使用劑量；激活glaxosmithkline 3500萬美元支付。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊